Given ARPC1B’s role in cytoskeletal dynamics and metastasis suppression, combining its inhibition with immune checkpoint blockade represents a promising strategy for metastatic ccRCC that may improve survival outcomes. This evidence concerns the gene ARPC1B and nonpapillary renal cell carcinoma.